OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment. - Optimise

Study identifier:D3560L00071

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment.

Medical condition

diabetes

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

4027

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Mar 2008

Primary Completion Date: 01 Jan 2010

Study Completion Date: 01 Jan 2010

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
1 Control group	-
2 Benchmarking group	-

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1353&filename=CSR-D3560L00071.pdf
Download
CSR-D3560L00071.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Belgium Clinical Study Information

32-2370-4320

[email protected]

Investigators

Principal Investigator

Hermans

UCL